Wednesday, 20 July 201108:00 | Registration | 09:00 |  | Keynote Presentation Towards a Regenerative Medicine for Multiple Sclerosis Robin Franklin, Professor, University of Cambridge, United Kingdom
This talk will describe how studies on science of adult neural stem cell differentiation can form the basis of drug-based regenerative medicines for demyelinating disease such as multiple sclerosis. |
| | Session: Human Embryonic Stem Cells (hESCs), Induced Pluripotent Stem Cells (iPSCs), and Epigenetic Reprogramming |
| | 09:30 | Signals, Stochastic and Epigenetic Factors Regulating Pluripotency and Cell Fate in Embryos and Stem Cells Claudio Stern, Professor, University College London, United Kingdom
This talk will discuss timing and cell heterogeneity in relation to pluripotency and the acquisition of neural fate in embryos in vivo and embryonic and gonocyte-derived stem cells in vitro. | 10:00 | Induction of Pluripotent Stem Cells Holm Zaehres, Professor, Max Planck Institute, Germany
This presentation will describe the current status of strategies to generate induced pluripotent stem (iPS) cells from mouse and human somatic cells for patient-specific disease modeling and cell therapeutic applications. | 10:30 | Coffee and Networking in Exhibition Hall | 11:15 | Clinical Grade Pluripotent Stem Cells - Where are We Now Dusko Ilic, Senior Lecturer/Reader, Kings College London, United Kingdom
| 11:45 | Generation of Chondrogenic Cells from Human Embryonic Stem Cells Sue Kimber, Professor of Stem Cells & Reproductive Biology, University of Manchester, United Kingdom
This talk will focus on the development of defined system for generation of chondrogenic cells from human ES cells with potential for cellular therapy. | 12:15 | A Defined System for Human Pluripotent Stem Cell Culture and Differentiation Poh Tan, Product Manager, Stemcell Technologies Inc, Canada
This talk will describe the use of a completely defined feeder-free based system for the culture and maintenance and differentiation of hPSCs. | 12:45 | Technology Spotlight: Meeting cGMP Requirements and Process Challenges for the Development of Viral-based Therapeutics Tim Calvert, Account Manager, Lonza Biosciences
| 13:00 | Lunch and Networking in Exhibition Hall | 13:30 | Poster Viewing Session | | Session Topic: Stem Cells Intellectual Property and Commercial Trends |
| | 14:15 |  | Keynote Presentation The Mandate to Deliver Cures : Aligning the Science, Industry and Patient-advocacy Agendas Bernard Siegel, Founder and Executive Director, Genetics Policy Institute, United States of America
Out of the ferocious public policy debates on the use of hESCs there emerged a “pro-cures” consumer movement. It is imperative that the pro-cures movement’s goals become aligned with the policy initiatives of industry and science with the aim of accelerating the translation of research into effective treatments and cures. |
| 14:45 | Stem Cells and the IP Landscape - Changing or Status Quo Philippa Montgomerie, Partner, DLA Piper, United Kingdom
| 15:15 | Coffee and Networking in Exhibition Hall | 16:00 | Stem Cell Legislation Across the EU - Trends, Pitfalls and Opportunities for Academic Research and Industry Timo Faltus, Research Associate, Martin-Luther-University, Germany
This presentation provides an overview of European stem cell regulations. The talk includes a comparison of the regulations in different EU countries and focuses on the current trends especially in German stem cell law. | 16:30 | Market Trends in Stem Cell Research and Cellular Therapy: Qualitative and Quantitative Analysis Enal Razvi, Managing Director, Select Biosciences Inc, United States of America
This talk presents a snapshot from the most-recent market analysis performed by Select Biosciences that characterizes the technology and commercial trends in stem cell research and cellular therapy. Quantitative market metrics frame the field in terms of segments, penetrance of various technologies/products/vendors, as well as the emerging themes in the deployment of different stem cell types for cellular therapy. | 17:00 | Panel Discussion - Scottish Stem Cell Network Michael Leek, Business Development Director, Immunosolv, United Kingdom
| 17:00 | Panel Discussion - Scottish Stem Cell Network Michael Leek, Business Development Director, Immunosolv, United Kingdom
| 18:00 | Drinks Reception |
Thursday, 21 July 201109:00 |  | Keynote Presentation Targeting Cancer Stem Cells Malcom Alison, Professor, Queen Mary University, United Kingdom
|
| | Session: Stem Cell Banking |
| | 09:30 | International Coordination of Stem Cell Banks Glyn Stacey, Director, UK Stem Cell Bank, United Kingdom
The study of human stem cell biology and delivery of cells for human therapy require careful standardisation and quality control. This lecture will look at the mechanisms by which these important support elements are delivered through an international network of stem cell banks delivering human stem cell lines for research and development. | 10:00 | The NHS Cord Blood Bank: 15 Years On Andrew Hadley, General Manager, NHS Blood and Transplant, United Kingdom
Stem cell transplantation using umbilical cord blood is firmly established as a curative treatment for patients with leukaemia. The UK's strategy for collecting and banking cord blood will be described and new approaches to expanding cord blood stem cells and improving post-transplant outcomes will be reviewed. | 10:30 | Coffee and Networking in Exhibition Hall | | Session: Cellular Therapy and Regenerative Medicine |
| | 11:15 | New Blood: Using Stem Cells to Generate Erythrocytes for Transfusion Jo Mountford, Lecturer, University of Glasgow, United Kingdom
| 11:45 | Use of Nanostructured Materials to Influence Mesenchymal Stem Cell Behaviour Matt Dalby, Reader, University of Glasgow, United Kingdom
The presentation will focus on nanoscale topographical features and the range of influence they can infer and the possible echantransductive mechanisms the cells may use. | 12:15 | Chemical Driving of Smad Gene Expression and Signaling Orchestrates Cardiogenesis in Mouse Embryonic and Human Mesenchymal Stem Cells Carlo Ventura, Professor, University of Bologna, Italy
The use of hyaluronan esters paves novel combinatorial strategies of molecular and stem cell cardiovascular therapy based on fine tuning of targeted Smad transcription and signaling. | 12:45 | Lunch and Networking in Exhibition Hall | 13:30 | Poster Viewing Session | 14:30 | Functional Improvement of Silica Fibrosis Murine Model by Human Embryonic Stem Cells Federica Sangiuolo, Assistant Professor, University of Rome Tor Vergata, Italy
This presentation will demonste the capacity of hES cells to differentiate into type II pneumocytes in vitro and to repair in vivo lung damage in silica fibrosis disease models. hES can be considered a promising way to cure lung fibrosis by a cell therapy approach. | 15:00 | An Endogenous Small RNA Specifies the Hematopoiesis of Mesenchymal Stem Cells by Repressing EID1 James Yin, Professor, Institute of Stem Cells, China
| 15:30 | Coffee and Networking in Exhibition Hall | 16:00 | Designing and Running a Phase I Trial of Neural Stem Cells in Stroke: PISCES (Preliminary Investigation of Stem Cells in Stroke) Experience Keith Muir, Professor, University of Glasgow, United Kingdom
| 16:30 | Heterogeneity of Tumour Cells Seeded into Blood as Analyzed by Multiplex PCR of Individual Cells Singled out by Micro-capillary Manipulation Katharina Pachmann, Senior Scientist, Universitätsklinikum Jena, Germany
| 17:00 | Close of Conference |
|